Regulus Therapeutics Inc (NASDAQ:RGLS) – Equities researchers at Wedbush issued their FY2022 EPS estimates for shares of Regulus Therapeutics in a note issued to investors on Thursday, according to Zacks Investment Research. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will post earnings of $0.47 per share for the year. Wedbush has a “Outperform” rating and a $4.00 price target on the stock.
Other analysts have also issued reports about the stock. Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Wednesday, January 24th. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. Chardan Capital reissued a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Finally, Leerink Swann initiated coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They set an “outperform” rating and a $2.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $2.50.
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down $0.02 during trading hours on Monday, hitting $1.20. 503,100 shares of the stock were exchanged, compared to its average volume of 564,792. The firm has a market cap of $124.75, a price-to-earnings ratio of -0.89 and a beta of 1.72. Regulus Therapeutics has a 12 month low of $0.79 and a 12 month high of $1.95. The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41.
Institutional investors have recently added to or reduced their stakes in the business. NEA Management Company LLC acquired a new position in Regulus Therapeutics in the 3rd quarter valued at approximately $13,737,000. Victory Capital Management Inc. bought a new stake in Regulus Therapeutics in the third quarter worth approximately $347,000. Goldman Sachs Group Inc. grew its position in Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 240,890 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new stake in Regulus Therapeutics in the third quarter worth approximately $750,000. Finally, South Dakota Investment Council grew its position in Regulus Therapeutics by 37.1% in the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after acquiring an additional 492,969 shares in the last quarter. Hedge funds and other institutional investors own 57.83% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.